ReviewTargeted oncology2024

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy.

Tomas Buchler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.